. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci. 2014 Jul 9;34(28):9441-54. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Antibody Against α-Synuclein Looks Safe In Phase 1

Therapeutics

  1. Prasinezumab

Research Models

  1. Thy1-αSyn “Line 61” Mouse